Effects of first‐line antidiabetic drugs on the improvement of arterial stiffness: A Bayesian network meta‐analysis

Jincheng Wang,Yuhan Wang,Yueheng Wang,Yu Li,Jiamei Zhang,Han Zhang,Xiaomin Fu,Zhiqin Guo,Ying Yang,Kaining Kang,Wei Zhang,Li Tian,Yanqiang Wu,Shuanli Xin,Hongzhou Liu

DOI: https://doi.org/10.1111/1753-0407.13405

IF: 4.53

2023-05-12

Journal of Diabetes

Abstract:Highlights Vascular complication is one of the most important causes of death in diabetes patients. Arterial stiffness plays a key role in the progress of diabetes vascular complication; therefore, the improvement of arterial stiffness could inhibit the process of atherosclerosis and reduce the burden of diabetes vascular complications This study first analyzed the potential antiarterial stiffness effect of six first‐line antidiabetic drugs, providing new strategies for personalized glucose‐lowering therapy. Background Changes in vascular function are closely associated with the development of cardiovascular disease (CVD). Pulse wave velocity (PWV) is a potential indicator of vascular dysfunction; it allows noninvasive assessment of arterial stiffness. Currently, evidence for the effects of different classes of antidiabetic drugs on arterial stiffness remains limited. In this study, a network meta‐analysis (NMA) was performed to explore the associations between changes in arterial stiffness and first‐line antidiabetic drugs by evaluating PWV in patients with different metabolic abnormalities. Methods We systematically searched several electronic databases for randomized controlled trials (RCTs) published from inception until 25 August 2022, without language restrictions. The primary outcome was the change in PWV (ΔPWV) in all included studies; subgroup analysis was performed for patients with abnormal glucose metabolism, including prediabetes and diabetes mellitus. NMA was performed to calculate the mean differences (MDs) with 95% confidence intervals (CIs) as effect sizes to evaluate the ΔPWV. Results Among the 2257 candidate articles identified in the initial search, 18 RCTs were eventually included in the analysis. In all studies, two classes of new antidiabetic drugs, glucagon‐like peptide‐1 receptor (GLP‐1R) agonists and sSodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors, improved arterial stiffness by decreasing PWV compared with placebo (MD = −1.11, 95% CI: −1.94 to 0.28) and (MD = −0.76, 95% CI: −1.45 to −0.08). A conventional antidiabetic drug, metformin, also showed similar efficacy compared with placebo (MD = −0.73, 95% CI: −1.33 to −0.12). Finally, in subgroup studies of patients with abnormal glucose metabolism diseases, GLP‐1R agonists (MD = −1.06, 95% CI: −2.05 to −0.10) significantly decreased PWV compared with placebo. Conclusion Three classes of antidiabetic drugs—GLP‐1R agonists, SGLT‐2 inhibitors, and metformin—have the potential to improve arterial stiffness. Among the six classes of antidiabetic drugs analyzed, GLP‐1R agonists constitute the only class of drugs that improves arterial stiffness in patients with abnormal glucose metabolism diseases.

endocrinology & metabolism